MSN: 'Human beings now have hope': UC doctor running Moderna trial says a big blow struck against coronavirus

Preliminary analysis shows vaccine has 95% efficacy

The preliminary analysis on the Moderna COVID-19 vaccine shows 94.5% efficacy, which is consistent with recent early results on the Pfizer vaccine. Carl Fichtenbaum, MD, of the UC Division of Infectious Diseases is a co-investigator of the trial on the Moderna vaccine being conducted at UC. 

a doctor working in a research laboratory

Carl Fichtenbaum, MD, of the UC Division of Infectious Diseases. Photo/Colleen Kelley/UC Creative + Brand

In a story published on MSN and Cincinnati.com, Fichtenbaum said “This is the beginning of the end because human beings now have hope.”

The Moderna vaccine candidate requires two injections 28 days apart. The Pfizer drug is delivered in two shots 21 days apart. 

The two vaccines are similar in technology, using a fragment of the virus’ genetic code to go after the spiky proteins on the surface of the coronavirus. Without the crown of spikes, the virus can’t bind, and the body develops the ability to recognize the virus and fight it off.

The Pfizer candidate requires super-cold storage, which many providers do not have. Fichtenbaum said Monday that the advantage of the Moderna candidate is that it keeps at -4, “and most hospitals in the United States have freezers that have the capacity of holding at that temperature.”

The drug also is stable, Fichtenbaum said, “and could be given in a church parking lot over a vaccination day without losing any efficacy. We have reason to be incredibly hopeful.”

Read the entire story here. 

Fichtenbaum was also interviewed on this topic by the Cincinnati Business Courier, WLWT-TV and 700 WLW radio. Margaret Powers-Fletcher, co-investigator with Fichtenbaum on the Moderna vaccine trial at UC, was interviewed by Spectrum News

Lead image/Colleen Kelley/UC Creative + Brand

Next Lives Here

The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.

Related Stories

2

High-dose vitamin C shows promise in pancreatic cancer treatment

December 17, 2024

The University of Cincinnati Cancer Center's Olugbenga Olowokure was featured in a Local 12 story discussing new research from the University of Iowa that suggests that high doses of vitamin C, when combined with standard chemotherapy, may significantly extend the life expectancy of patients with advanced pancreatic cancer.

Debug Query for this